Personal information

Other IDs

Scopus Author ID: 56392864300

Countries

Italy

Activities

Collapse all

Employment (1)

Ospedale Papa Giovanni XXIII: Bergamo, Lombardia, IT

2019-05-27 to present | Medical Doctor (Hematology and Bone Marrow Transplant Unit)
Employment
Source: Self-asserted source
Marco Frigeni

Works (25)

Adapting the Fitness Criteria for Non-Intensive Treatments in Older Patients with Acute Myeloid Leukemia to the Use of Venetoclax-Hypomethylating Agents Combination—Practical Considerations from the Real-Life Experience of the Hematologists of the Rete Ematologica Lombarda

Cancers
2024 | Journal article
DOI: 10.3390/cancers16020386
EID:

2-s2.0-85183446550

Part of ISSN: 20726694
Contributors: Rossi, G.; Borlenghi, E.; Zappasodi, P.; Lussana, F.; Bernardi, M.; Basilico, C.; Molteni, A.; Lotesoriere, I.; Turrini, M.; Frigeni, M. et al.
Source: Self-asserted source
Marco Frigeni via Scopus - Elsevier
grade
Preferred source (of 2)‎

Molecular prognostication for transplant decision making of patients with myelodysplastic syndromes: A retrospective single-center study

Leukemia Research
2024 | Journal article
DOI: 10.1016/j.leukres.2024.107529
EID:

2-s2.0-85194401980

Part of ISSN: 18735835 01452126
Contributors: Condorelli, A.; Frigeni, M.; Quaresmini, G.; Salmoiraghi, S.; Pavoni, C.; Grassi, A.; Raviglione, M.; Civini, A.; Putelli, A.; Lussana, F. et al.
Source: Self-asserted source
Marco Frigeni via Scopus - Elsevier

Methodology and clinical utility of longitudinal UBA1 tracking in VEXAS syndrome.

British journal of haematology
2024-11-13 | Journal article
DOI: 10.1111/bjh.19897
PMID: 39533868
Contributors: CARMELO GURNARI; Galossi E; Lumia E; Piciocchi A; Divona M; Casciani E; Romano F; Diral E; Alessandro Tomelleri; Caroni F et al.
Source: Self-asserted source
Marco Frigeni
grade
Preferred source (of 2)‎

Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort

American Journal of Hematology
2024-02 | Journal article
DOI: 10.1002/ajh.27169
Part of ISSN: 0361-8609
Part of ISSN: 1096-8652
Contributors: CARMELO GURNARI; Maria Rosaria Pascale; Antonio Vitale; Elisa Diral; Alessandro Tomelleri; Elisa Galossi; Giulia Falconi; Alessandro Bruno; Francesca Crisafulli; Micol Frassi et al.
Source: Self-asserted source
Marco Frigeni
grade
Preferred source (of 2)‎

Real-World Efficacy and Safety of Luspatercept in Adult Patients with Transfusion-Dependent Anaemia Due to Lower-Risk Myelodysplastic Syndromes with Ring Sideroblasts (MDS-RS), Who Had an Unsatisfactory Response to or are Ineligible for Erythropoiesis Stimulating Agents: A Retrospective, Multicenter, Cohort Study

SSRN
2023 | Other
DOI: 10.2139/ssrn.4313690
EID:

2-s2.0-85177993656

Part of ISSN: 15565068
Contributors: Lanino, L.; Restuccia, F.; Perego, A.; Ubezio, M.; Fattizzo, B.; Riva, M.; Consagra, A.; Musto, P.; Cilloni, D.; Natalie Oliva, E. et al.
Source: Self-asserted source
Marco Frigeni via Scopus - Elsevier

Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts.

American journal of hematology
2023-05-24 | Journal article
DOI: 10.1002/ajh.26960
PMID: 37222267
Contributors: Luca Lanino; Francesco Restuccia; Perego A; Ubezio M; Fattizzo B; Riva M; Consagra A; Musto P; daniela cilloni; Oliva EN et al.
Source: Self-asserted source
Marco Frigeni
grade
Preferred source (of 2)‎

Correction: Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19 (Leukemia, (2021), 35, 9, (2710-2714), 10.1038/s41375-021-01299-x)

Leukemia
2021 | Journal article
DOI: 10.1038/s41375-021-01329-8
EID:

2-s2.0-85115449149

Part of ISSN: 14765551 08876924
Contributors: Gritti, G.; Raimondi, F.; Bottazzi, B.; Ripamonti, D.; Riva, I.; Landi, F.; Alborghetti, L.; Frigeni, M.; Damiani, M.; Micò, C. et al.
Source: Self-asserted source
Marco Frigeni via Scopus - Elsevier

Concurrent Diagnosis of Acute Myeloid Leukemia and Symptomatic COVID-19 Infection: a Case Report Successfully Treated with Azacitidine-Venetoclax Combination.

Mediterranean journal of hematology and infectious diseases
2021-09-01 | Journal article
DOI: 10.4084/mjhid.2021.057
PMID: 34527209
PMC: PMC8425345
Source: Self-asserted source
Marco Frigeni
grade
Preferred source (of 2)‎

Mutational and immunogenetic landscape of <scp>HCV</scp> ‐associated B‐cell lymphoproliferative disorders

American Journal of Hematology
2021-06 | Journal article
DOI: 10.1002/ajh.26167
Part of ISSN: 0361-8609
Part of ISSN: 1096-8652
Source: Self-asserted source
Marco Frigeni
grade
Preferred source (of 2)‎

Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19.

Leukemia
2021-05-24 | Journal article
DOI: 10.1038/s41375-021-01299-x
PMID: 34031531
PMC: PMC8142063
Source: Self-asserted source
Marco Frigeni
grade
Preferred source (of 2)‎

IL-6 signalling pathway inactivation with siltuximab in patients with COVID-19 respiratory failure: An observational cohort study

medRxiv
2020 | Other
DOI: 10.1101/2020.04.01.20048561
EID:

2-s2.0-85098830210
Contributors: Gritti, G.; Raimondi, F.; Ripamonti, D.; Riva, I.; Landi, F.; Alborghetti, L.; Frigeni, M.; Damiani, M.; Micò, C.; Fagiuoli, S. et al.
Source: Self-asserted source
Marco Frigeni via Scopus - Elsevier

Endothelial Injury and Thrombotic Microangiopathy in COVID-19: Treatment with the Lectin-Pathway Inhibitor Narsoplimab

Immunobiology
2020-08 | Journal article
DOI: 10.1016/j.imbio.2020.152001
Part of ISSN: 0171-2985
Source: Self-asserted source
Marco Frigeni
grade
Preferred source (of 2)‎

Targeted next‐generation sequencing reveals molecular heterogeneity in non‐chronic lymphocytic leukemia clonal B‐cell lymphocytosis

Hematological Oncology
2020-08-19 | Journal article
DOI: 10.1002/hon.2784
Part of ISSN: 0278-0232
Part of ISSN: 1099-1069
Source: Self-asserted source
Marco Frigeni
grade
Preferred source (of 2)‎

Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphoma.

Leukemia & lymphoma
2020-04-28 | Journal article
DOI: 10.1080/10428194.2020.1755859
PMID: 32343165
Source: Self-asserted source
Marco Frigeni
grade
Preferred source (of 2)‎

Hepatitis B virus-associated B-cell non-Hodgkin lymphoma in non-endemic areas in Western Europe: Clinical characteristics and prognosis.

The Journal of infection
2019-12-14 | Journal article
DOI: 10.1016/j.jinf.2019.12.005
PMID: 31846632
Source: Self-asserted source
Marco Frigeni
grade
Preferred source (of 2)‎

Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection.

Leukemia
2019-12-13 | Journal article
DOI: 10.1038/s41375-019-0687-2
PMID: 31836855
Source: Self-asserted source
Marco Frigeni
grade
Preferred source (of 2)‎

Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study.

Blood
2019-07-10 | Journal article
DOI: 10.1182/blood.2019001088
PMID: 31292118
Source: Self-asserted source
Marco Frigeni
grade
Preferred source (of 2)‎

Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network.

Hematological oncology
2019-02-22 | Journal article
DOI: 10.1002/hon.2575
PMID: 30726562
Source: Self-asserted source
Marco Frigeni
grade
Preferred source (of 3)‎

Low-Grade Lymphomas (Other than CLL/SLL) in Older Patients

2018 | Book chapter
DOI: 10.1007/978-3-319-44870-1_41-1
Part of DOI: 10.1007/978-3-319-57415-8_41
Part of ISBN: 9783319448701
EID:

2-s2.0-85085453717

ISBN: 9783319574158 9783319574141
Source: Self-asserted source
Marco Frigeni
grade
Preferred source (of 2)‎

Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas.

The oncologist
2018-12-14 | Journal article
DOI: 10.1634/theoncologist.2018-0331
PMID: 30552159
Source: Self-asserted source
Marco Frigeni
grade
Preferred source (of 3)‎

Direct-acting antivirals during or after immunochemotherapy in hepatitis C virus–positive diffuse large B-cell lymphomas

Hepatology
2017 | Journal article
DOI: 10.1002/hep.29198
EID:

2-s2.0-85028297070

Part of ISSN: 15273350 02709139
Contributors: Merli, M.; Frigeni, M.; Gotti, M.; Grossi, P.; Bruno, R.; Passamonti, F.; Arcaini, L.
Source: Self-asserted source
Marco Frigeni via Scopus - Elsevier
grade
Preferred source (of 2)‎

Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection

Blood
2016 | Journal article
DOI: 10.1182/blood-2016-05-714667
EID:

2-s2.0-85015085713

Part of ISSN: 15280020 00064971
Contributors: Arcaini, L.; Besson, C.; Frigeni, M.; Fontaine, H.; Goldaniga, M.; Casato, M.; Visentini, M.; Torres, H.A.; Loustaud-Ratti, V.; Peveling-Oberhag, J. et al.
Source: Self-asserted source
Marco Frigeni via Scopus - Elsevier

Independent prognostic impact of tumour-infiltrating macrophages in early-stage Hodgkin's lymphoma.

Hematological oncology
2016-04-06 | Journal article
DOI: 10.1002/hon.2295
PMID: 27060262
Source: Self-asserted source
Marco Frigeni
grade
Preferred source (of 3)‎

Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: A nationwide retrospective survey from Italy

Bone Marrow Transplantation
2015 | Journal article
DOI: 10.1038/bmt.2014.231
EID:

2-s2.0-84922330557

Part of ISSN: 14765365 02683369
Contributors: Girmenia, C.; Rossolini, G.M.; Piciocchi, A.; Bertaina, A.; Pisapia, G.; Pastore, D.; Sica, S.; Severino, A.; Cudillo, L.; Ciceri, F. et al.
Source: Self-asserted source
Marco Frigeni via Scopus - Elsevier
grade
Preferred source (of 2)‎

Childhood myelodysplastic syndrome associated with an acquired Bernard-Soulier-like platelet dysfunction

Blood
2014 | Journal article
DOI: 10.1182/blood-2014-08-587832
EID:

2-s2.0-84908141394

Part of ISSN: 15280020 00064971
Contributors: Frigeni, M.; Galli, M.
Source: Self-asserted source
Marco Frigeni via Scopus - Elsevier
How many people are using ORCID?